Monte Rosa Therapeutics (GLUE) Assets Average (2023 - 2025)
Historic Assets Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $409.7 million.
- Monte Rosa Therapeutics' Assets Average rose 2430.74% to $409.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.7 million, marking a year-over-year increase of 2430.74%. This contributed to the annual value of $371.2 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Assets Average of $409.7 million as of Q3 2025, which was up 2430.74% from $376.4 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Assets Average's 5-year high stood at $416.0 million during Q1 2025, with a 5-year trough of $265.4 million in Q3 2023.
- Over the past 3 years, Monte Rosa Therapeutics' median Assets Average value was $317.5 million (recorded in 2024), while the average stood at $333.6 million.
- Per our database at Business Quant, Monte Rosa Therapeutics' Assets Average skyrocketed by 395.07% in 2024 and then skyrocketed by 4582.46% in 2025.
- Monte Rosa Therapeutics' Assets Average (Quarter) stood at $277.9 million in 2023, then surged by 35.61% to $376.9 million in 2024, then grew by 8.7% to $409.7 million in 2025.
- Its Assets Average stands at $409.7 million for Q3 2025, versus $376.4 million for Q2 2025 and $416.0 million for Q1 2025.